Add to ORKGFull list of author information is available at the end of the articlematched frozen tissue. In addition, the SRM assay was applied to a collection of histologically-characterized FFPE NSCLC patient tumor tissue where EGFR levels were quantitated from not detected (ND) to 670amol/μg. Conclusions: This report describes and evaluates the performance of a robust and reproducible SRM assay designed for measuring EGFR directly in FFPE patient tumor tissue with accuracy at extremely low (attomolar) levels. This assay can be used as part of a complementary or companion diagnostic strategy to support novel therapies currently under development and demonstrates the potential to identify candidates for EGFR-inhibitor therapy
The epidermal growth factor receptor (EGFR) is overexpressed in 50-70% of human primary breast, lung...
Alteration of EGFR at the gene and/or protein level has been found in diverse carcinoma types. EGFR ...
The search for novel and clinically relevant biomarkers still represents a major clinical challenge ...
Abstract Background Analysis of key therapeutic targets such as epidermal growth factor receptor (EG...
Objectives Epidermal growth factor receptor (EGFR) gene mutations in tumors predict tumor response t...
The data presented here describes the use of targeted proteomic assays to quantify potential biomark...
Epidermal growth factor receptor (EGFR) gene mutations in tumors predict tumor response to EGFR tyro...
Clinical oncology is hampered by lack of tools to accurately assess a patient’s response to pathway-...
Background: The validity of epidermal growth factor receptor (EGFR) mutation in serum and plasma DNA...
Tyrosine kinase inhibitors of epidermal growth factor receptor (EGFR-TKIs) are standard treatments f...
Background: EGFR and its downstream signaling pathway are important targets for cancer therapy. Rece...
IntroductionThe potential to accurately quantify epidermal growth factor receptor (EGFR) mutations i...
Non-small cell lung cancer (NSCLC) has one of the highest cancer-related mortality rates worldwide. ...
Abstract Purpose: Epidermal growth factor receptor variant III (EGFRvIII) is an oncogenic, constitut...
<p>A: 0 mg/kg As<sub>2</sub>O<sub>3</sub> (control). The strongest red-brownish membrane-bound immun...
The epidermal growth factor receptor (EGFR) is overexpressed in 50-70% of human primary breast, lung...
Alteration of EGFR at the gene and/or protein level has been found in diverse carcinoma types. EGFR ...
The search for novel and clinically relevant biomarkers still represents a major clinical challenge ...
Abstract Background Analysis of key therapeutic targets such as epidermal growth factor receptor (EG...
Objectives Epidermal growth factor receptor (EGFR) gene mutations in tumors predict tumor response t...
The data presented here describes the use of targeted proteomic assays to quantify potential biomark...
Epidermal growth factor receptor (EGFR) gene mutations in tumors predict tumor response to EGFR tyro...
Clinical oncology is hampered by lack of tools to accurately assess a patient’s response to pathway-...
Background: The validity of epidermal growth factor receptor (EGFR) mutation in serum and plasma DNA...
Tyrosine kinase inhibitors of epidermal growth factor receptor (EGFR-TKIs) are standard treatments f...
Background: EGFR and its downstream signaling pathway are important targets for cancer therapy. Rece...
IntroductionThe potential to accurately quantify epidermal growth factor receptor (EGFR) mutations i...
Non-small cell lung cancer (NSCLC) has one of the highest cancer-related mortality rates worldwide. ...
Abstract Purpose: Epidermal growth factor receptor variant III (EGFRvIII) is an oncogenic, constitut...
<p>A: 0 mg/kg As<sub>2</sub>O<sub>3</sub> (control). The strongest red-brownish membrane-bound immun...
The epidermal growth factor receptor (EGFR) is overexpressed in 50-70% of human primary breast, lung...
Alteration of EGFR at the gene and/or protein level has been found in diverse carcinoma types. EGFR ...
The search for novel and clinically relevant biomarkers still represents a major clinical challenge ...